Mechanism of Action
Y Receptor Subtypes
NPY acts on Y1-Y5 receptors, all Gi-coupled GPCRs that inhibit adenylyl cyclase and reduce cAMP. Y1 and Y5 in hypothalamic PVN mediate the potent appetite-stimulating effects; a single ICV injection of NPY in rodents produces hyperphagia lasting several hours. Y2 receptors function as autoreceptors on NPY neurons, providing feedback inhibition of NPY release. Y2/Y4 agonism by PYY3-36 and pancreatic polypeptide contributes to postprandial satiety, opposing NPY's orexigenic action.
Sympathetic and Cardiovascular Effects
NPY is co-released with norepinephrine from sympathetic nerve terminals, potentiating vasoconstriction through Y1 receptors on vascular smooth muscle. NPY modulates heart rate, blood pressure, and coronary vasoreactivity. During stress, elevated plasma NPY contributes to visceral fat deposition and stress-induced cardiometabolic dysfunction. NPY's role in stress-related obesity is an active research area.
Interaction with Leptin and the Obese State
leptin/" class="wiki-internal-link">Leptin deficiency (or leptin resistance in obesity) disinhibits NPY/AgRP neurons, resulting in elevated NPY tone, increased appetite, and reduced energy expenditure. This NPY hyperactivity is a key mechanism of hypothalamic obesity regulation breakdown. Interventions targeting NPY release (GLP-1 agonists indirectly reduce NPY activity) or NPY receptors are considered promising adjuncts to current obesity therapy.
Research Summary
Appetite and Obesity
Preclinical StrongExtensive rodent data: chronic ICV NPY infusion produces hyperphagia, obesity, and metabolic syndrome. NPY knockout mice show reduced weight gain on high-fat diet. Y1 and Y5 antagonists reduce food intake in animal models. Phase 2 trials of Y5 receptor antagonists (velneperit, S-2367) produced modest but significant weight loss in humans, confirming translational relevance. Combined Y1/Y5 blockade strategies being explored.
Anxiety and PTSD
Active ResearchNPY in the amygdala and locus coeruleus modulates fear extinction and stress resilience. Lower CSF NPY levels correlate with PTSD severity and combat stress exposure. Intranasal NPY administration reduced anxiety in healthy subjects and is in Phase 2 trials for PTSD. NPY may be a resilience peptide: high central NPY is associated with better stress adaptation in elite soldiers.
Cardiovascular and Metabolic Syndrome
Active ResearchPlasma NPY is elevated in hypertension, metabolic syndrome, and stress-related cardiovascular disease. Y1 receptor antagonists reduce blood pressure in animal models. NPY-driven sympathetic activation contributes to visceral adiposity -- the "stress fat" phenotype. Understanding NPY in stress-obesity interactions may guide combined metabolic-psychiatric treatment approaches.
Calculate your Neuropeptide Y dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| PTSD/anxiety research (human) | Intranasal NPY 50-100 nmol (in Phase 2 trials) | Single dose per session | Intranasal |
| Appetite/metabolic research (rodent) | 1-10 nmol ICV injection or 5-50 nmol/kg IP | Single or repeated doses | Intracerebroventricular or intraperitoneal |
Human NPY research primarily targets intranasal delivery for CNS access without peripheral effects. Systemic NPY produces vasoconstriction; CNS-selective delivery is preferred.
Interactions
Safety Profile
Intranasal NPY in Phase 2 trials is well tolerated with no serious adverse events reported. IV NPY causes dose-dependent hypertension and coronary vasoconstriction -- limits systemic use to controlled research settings. The strong orexigenic effect means exogenous NPY could worsen obesity if given systemically. Peripheral NPY effects (vasoconstriction, elevated BP) represent the main safety concern for non-CNS-targeted delivery routes. No carcinogenicity, hepatic, or renal safety concerns identified with acute dosing.
References
- [1]Tatemoto K, et al. Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296(5858):659-660.
- [2]Rasmusson AM, et al. Lower cerebrospinal fluid neuropeptide Y (NPY) levels in combat veterans with posttraumatic stress disorder. Neuropsychopharmacology. 2000;23(4):428-440.
- [3]Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38(4):213-224.